Litcius/Paper detail

Innovative design and synthesis of dual-acting hCA IX/CDK-2 inhibitors through hetero ring fused pyrimidine utilization for cutting-edge anticancer therapy: Zein nanoparticles for in vivo lung cancer treatment

Heba M. Abosalim, Tarek F. El‐Moselhy, Nabaweya Sharafeldin, Simone Giovannuzzi, Paloma Begines, Mohamed S. Nafie, Sherif Ashraf Fahmy, Mohamed K. Diab, Asaad Babker, Claudiu T. Supuran, Mervat H. El‐Hamamsy, Haytham O. Tawfik

2025Bioorganic Chemistry19 citationsDOI

Topics & Concepts

ChemistryIn vivoZeta potentialA549 cellPyrimidineApoptosisCancer cellIn vitroLung cancerBiochemistryCarbonic anhydraseTreatment of lung cancerNanoparticleDownregulation and upregulationEx vivoCancer researchPharmacologyCancerCellDispersityEnzymeBiophysicsCell growthCytotoxicityAdvanced Breast Cancer TherapiesSynthesis and Biological EvaluationSynthesis and biological activity
Innovative design and synthesis of dual-acting hCA IX/CDK-2 inhibitors through hetero ring fused pyrimidine utilization for cutting-edge anticancer therapy: Zein nanoparticles for in vivo lung cancer treatment | Litcius